Missed Opportunities in Geriatric Oncology Research
1Wilmot Cancer Institute Geriatric Oncology Research Group, University of Rochester, Rochester, NY, USA.
The Oncologist
|March 20, 2023
Summary
Geriatric oncology clinical trials need more older adults (75+) and comprehensive data collection. Improved trial design and reporting are crucial for advancing cancer care in the elderly population.
Area of Science:
- Geriatric Oncology
- Clinical Trials
- Cancer Research
Background:
- Geriatric oncology has advanced, yet older adults, especially those 75+, remain underrepresented in clinical trials.
- This underrepresentation leads to a deficit in high-quality data for treating elderly cancer patients.
- The American Society of Clinical Oncology advocates for a stronger evidence base for this demographic.
Purpose of the Study:
- To identify and address missed opportunities in geriatric oncology research.
- To improve the inclusion of older adults in clinical trials.
- To enhance data collection and analysis for geriatric oncology.
Main Methods:
- Review of current clinical trial practices in geriatric oncology.
- Analysis of data collection gaps concerning older patient populations.
- Examination of reporting standards for age-related data in cancer trials.
Main Results:
- Significant underrepresentation of patients aged 75+ in clinical trials.
- Missed opportunities in collecting crucial patient data (medications, social support, financial status).
- Inadequate analysis and reporting of age-specific data in trial results (e.g., median age only).
Conclusions:
- Geriatric oncology research requires better representation of older patients in clinical trials.
- Essential data on older patients must be systematically collected and analyzed.
- Improved data analysis and reporting are vital for advancing cancer care in the elderly.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.7K
Related Concept Videos
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
01:21Cancer Survival Analysis
407
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
407
01:11Clinical Trials: Overview
3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K